Experience with monoclonal antibodies against nontumour-specific antigens such as CD20 and EGFR (Tobinai, 2002; Goldberg, 2005) suggests that the enhanced expression of TfR on tumour cells and the targeting effect of Tf–Hp may provide an effective therapeutic window. Here, EGFR is linked to neoplasm.